Plasma Protease C1-inhibitor Treatment

World Market Report

MCP16695

EXECUTIVE ENGAGEMENTS

POOL

432
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

86
Interactions with Platform & by Email

PARTICIPANTS

17
Unique # Participated

VALIDATIONS

7
Responses Validated*

COMPANIES

46
Responses Validated*
* Login for a full stack data experience

DATE

OCT 2022

TABLES

123

PAGES

196

EDITION

7

PRICE

USD 4950

CODE

MCP16695


COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)

RANK

(S/A/N/T)

%

VALIDATED RESEARCH *

* S = Strong; A = Active; N = Niche; T= Trivial (<1%)
* Login to Participate & View Data Stacks
* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlassTM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.
View All Companies...

PARTICIPATE NOW!
RESEARCH MODULES EXECUTIVES
  

HIGHLIGHTS & REPORT INDEX

What's New for 2022?

» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year

Global Plasma Protease C1-inhibitor Treatment Market to Reach $9.1 Billion by 2027
In the changed post COVID-19 business landscape, the global market for Plasma Protease C1-inhibitor Treatment estimated at US$2.6 Billion in the year 2020, is projected to reach a revised size of US$9.1 Billion by 2027, growing at a CAGR of 19.8% over the analysis period 2020-2027. C1-Inhibitor, one of the segments analyzed in the report, is projected to record a 18.2% CAGR and reach US$4.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Kallikrein Inhibitor (Kalbitor) segment is readjusted to a revised 19.9% CAGR for the next 7-year period.

The U.S. Market is Estimated at $765.6 Million, While China is Forecast to Grow at 19.1% CAGR
The Plasma Protease C1-inhibitor Treatment market in the U.S. is estimated at US$765.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2027 trailing a CAGR of 19.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.6% and 17.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 14.6% CAGR.
Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Segment to Record 23.5% CAGR
In the global Selective Bradykinin B2 Receptor Antagonist (Firazyr)) segment, USA, Canada, Japan, China and Europe will drive the 23.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$406.9 Million in the year 2020 will reach a projected size of US$1.8 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.

SELECT PLAYERS

AbbVie; Alexion; Argenx; Bluebird Bio; Bristol-Myers Squibb/Celgene; CSL Limited; FibroGen; Gilead; GlaxoSmithKline; Novartis; Pharming Group N.V.; Sanquin; Shire plc; Vertex

SEGMENTS

» Distribution Channel (Hospital Pharmacies, Independent Pharmacies) » Dosage Type (Lyophilized, Liquid/Injectable) » Drug Class (C1-Inhibitor, Kallikrein Inhibitor (Kalbitor), Selective Bradykinin B2 Receptor Antagonist (Firazyr)))

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Plasma Protease C1-inhibitor Treatment – Global Key Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Plasma Protease C1-inhibitor Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for C1-Inhibitor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for C1-Inhibitor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for C1-Inhibitor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Kallikrein Inhibitor (Kalbitor) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Kallikrein Inhibitor (Kalbitor) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Kallikrein Inhibitor (Kalbitor) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Selective Bradykinin B2 Receptor Antagonist (Firazyr)) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Selective Bradykinin B2 Receptor Antagonist (Firazyr)) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Selective Bradykinin B2 Receptor Antagonist (Firazyr)) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Lyophilized by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Lyophilized by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Lyophilized by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Liquid/Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Liquid/Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Liquid/Injectable by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Independent Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Independent Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Independent Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Plasma Protease C1-inhibitor Treatment Market Analysis of Annual Sales in US$ Million for Years 2012 through 2027
UNITED STATES
Plasma Protease C1-inhibitor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
USA Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2021 & 2027
USA Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2021 & 2027
USA Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2021 & 2027
CANADA
Canada Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2021 & 2027
Canada Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2021 & 2027
Canada Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2021 & 2027
JAPAN
Plasma Protease C1-inhibitor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
Japan Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2021 & 2027
Japan Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2021 & 2027
Japan Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2021 & 2027
CHINA
Plasma Protease C1-inhibitor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
China Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2021 & 2027
China Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2021 & 2027
China Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2021 & 2027
EUROPE
Plasma Protease C1-inhibitor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
Europe Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Europe Historic Review for Plasma Protease C1-inhibitor Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2021 & 2027
Europe Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2021 & 2027
Europe Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2021 & 2027
Europe Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2021 & 2027
FRANCE
Plasma Protease C1-inhibitor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
France Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2021 & 2027
France Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2021 & 2027
France Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2021 & 2027
GERMANY
Plasma Protease C1-inhibitor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
Germany Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2021 & 2027
Germany Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2021 & 2027
Germany Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2021 & 2027
ITALY
Italy Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2021 & 2027
Italy Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2021 & 2027
Italy Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2021 & 2027
UNITED KINGDOM
Plasma Protease C1-inhibitor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
UK Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2021 & 2027
UK Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2021 & 2027
UK Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2021 & 2027
REST OF EUROPE
Rest of Europe Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2021 & 2027
Rest of Europe Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2021 & 2027
Rest of Europe Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2021 & 2027
ASIA-PACIFIC
Plasma Protease C1-inhibitor Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
Asia-Pacific Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2021 & 2027
Asia-Pacific Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2021 & 2027
Asia-Pacific Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2021 & 2027
REST OF WORLD
Rest of World Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Plasma Protease C1-inhibitor Treatment by Drug Class - C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Drug Class - Percentage Breakdown of Value Sales for C1-Inhibitor, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr)) for the Years 2012, 2021 & 2027
Rest of World Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Plasma Protease C1-inhibitor Treatment by Dosage Type - Lyophilized and Liquid/Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Dosage Type - Percentage Breakdown of Value Sales for Lyophilized and Liquid/Injectable for the Years 2012, 2021 & 2027
Rest of World Recent Past, Current & Future Analysis for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Hospital Pharmacies and Independent Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Plasma Protease C1-inhibitor Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Independent Pharmacies for the Years 2012, 2021 & 2027

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com